Aging-US

BUFFALO, NY- January 30, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.”

X-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of various human malignancies. However, a comprehensive pan-cancer analysis investigating the prognostic value, immunological functions, and epigenetic associations of XRCC1 remains lacking.

In this new study, researchers Guobing Wang, Yunyue Li, Rui Pan, Xisheng Yin, Congchao Jia, Yuchen She, Luling Huang, Guanhu Yang, Hao Chi, and Gang Tian from Southwest Medical University, The Affiliated Hospital of Southwest Medical University, Yibin Hospital of T.C.M, Medical School of Nanchang University, Fourth Military Medical University, and Ohio University aimed to address this knowledge gap by conducting a systematic investigation employing bioinformatics techniques across 33 cancer types.

“Our analysis encompassed XRCC1 expression levels, prognostic and diagnostic implications, epigenetic profiles, immune and molecular subtypes, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), immune checkpoints, and immune infiltration, leveraging data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases.”

Notably, XRCC1 displayed both positive and negative correlations with prognosis across different tumors. Epigenetic analysis revealed associations between XRCC1 expression and DNA methylation patterns in 10 cancer types, as well as enhanced phosphorylation. Furthermore, XRCC1 expression demonstrated associations with TMB and MSI in the majority of tumors.

Interestingly, XRCC1 gene expression exhibited a negative correlation with immune cell infiltration levels, except for a positive correlation with M1 and M2 macrophages and monocytes in most cancers. Additionally, the researchers observed significant correlations between XRCC1 and immune checkpoint gene expression levels. Lastly, their findings implicated XRCC1 in DNA replication and repair processes, shedding light on the precise mechanisms underlying its oncogenic effects.

“Overall, our study highlights the potential of XRCC1 as a prognostic and immunological pan-cancer biomarker, thereby offering a novel target for tumor immunotherapy."

DOI - https://doi.org/10.18632/aging.205426

Corresponding authors - Guanhu Yang - [email protected], Hao Chi - [email protected], and Gang Tian - [email protected]

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, X-ray repair cross-complementation group 1, pan-cancer, prognosis, immune infiltration, tumor microenvironment

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Visit our website at https://www.Aging-US.com​​ and connect with us:

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

BUFFALO, NY- January 24, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.”

Research has demonstrated that some tumor cells can transform into drug-tolerant persisters (DTPs), which serve as a reservoir for the recurrence of the disease. In this new study, researchers Yang-Che Wu, Chin-Sheng Huang, Ming-Shou Hsieh, Chih-Ming Huang, Syahru Agung Setiawan, Chi-Tai Yeh, Kuang-Tai Kuo, and Shao-Cheng Liu from Taipei Medical University-Shuang Ho Hospital, Taipei Medical University, Taitung Mackay Memorial Hospital, Tajen University, National Taitung University, and Taipei City’s National Defense Medical Center investigated lipid-metabolism-driven ferroptosis and its role in drug resistance and DTP generation in head and neck squamous cell carcinoma (HNSCC).

“The regulatory roles of ferroptosis suppressor protein 1 (FSP1) in HNSCC metabolic regulation were investigated.”

High levels of FSP1 were discovered in the tissues of patients who experienced relapse after cisplatin treatment. RNA sequencing indicated that a series of genes related to lipid metabolism were also highly expressed in tissues from these patients. Consistent results were obtained in primary DTP cells isolated from patients who experienced relapse. The Cancer Genome Atlas database confirmed this finding. This revealed that the activation of drug resistance in cancer cells is influenced by FSP1, intracellular iron homeostasis, and lipid metabolism.

Next, the team generated human oral squamous cell carcinoma DTP cells (HNSCC cell line) to cisplatin and observed higher expression of FSP1 and lipid-metabolism-related targets in vitro. The shFSP1 blockade attenuated HNSCC-DTP cell stemness and downregulated tumor invasion and the metastatic rate. They found that cisplatin induced FSP1/ACSL4 axis expression in HNSC-DTPC cells. Finally, the researchers evaluated the HNSCC CSC-inhibitory functions of iFSP1 (a metabolic drug and ferroptosis inducer) used for neo-adjuvant chemotherapy; this was achieved by inducing ferroptosis in a patient-derived xenograft mouse model.

“The present findings elucidate the link between iron homeostasis, ferroptosis, and cancer metabolism in HNSCC-DTP generation and acquisition of chemoresistance. The findings may serve as a suitable model for cancer treatment testing and prediction of precision treatment outcomes. In conclusion, this study provides clinically oriented platforms for evaluating metabolism-modulating drugs (FSP1 inhibitors) and new drug candidates of drug resistance and ferroptotic biomarkers.”

Corresponding authors - Ming-Shou Hsieh - [email protected], and Shao-Cheng Liu - [email protected]

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

BUFFALO, NY- January 23, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “Systematic analysis of the prognostic value and immunological function of LTBR in human cancer.”

Lymphotoxin beta receptor (LTBR) is a positive T cell proliferation regulator gene. It is closely associated with the tumor immune microenvironment. However, its role in cancer and immunotherapy is unclear.

In this new study, researchers Yinteng Wu, Shijian Zhao, Wenliang Guo, Ying Liu, Marìa Del Mar Requena Mullor, Raquel Alarcòn Rodrìguez, and Ruqiong Wei from The First Affiliated Hospital of Guangxi Medical University, The Eighth Affiliated Hospital of Guangxi Medical University and University of Almerìa analyzed the expression level and prognostic value of LTBR in clinical stages, immune subtypes, and molecular subtypes. The correlation between LTBR and immune regulatory genes, immune checkpoint genes, and RNA modification genes was then analyzed. Correlations between LTBR and immune cells, scores, cancer-related functional status, tumor stemness index, mismatch repair (MMR) genes, and DNA methyltransferase were also analyzed.

In addition, the team analyzed the role of LTBR in DNA methylation, mutational status, tumor mutation burden (TMB), and microsatellite instability (MSI). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were used to explore the role of LTBR in pan-cancer. Finally, the drugs associated with LTBR were analyzed.

“In this work, we looked into the expression of LTBR at multiple levels.”

The expression of LTBR was confirmed using quantitative real-time PCR and Western blot. LTBR is significantly overexpressed in most cancers and is associated with low patient survival. In addition, LTBR expression was strongly correlated with immune cells, score, cancer-related functional status, tumor stemness index, MMR genes, DNA methyltransferase, DNA methylation, mutational status, TMB, and MSI. Enrichment analysis revealed that LTBR was associated with apoptosis, necroptosis, and immune-related pathways. Finally, multiple drugs targeting LTBR were identified. LTBR is overexpressed in several tumors and is associated with a poor prognosis. It is related to immune-related genes and immune cell infiltration.

“Notably, we identified LTBR as a potential target for cancer immunotherapy and a marker of immune infiltration and poor prognosis. This study offers new possibilities for the diagnosis and treatment of cancer patients, instilling hope for improved outcomes.”

DOI - https://doi.org/10.18632/aging.205356

Corresponding author - Ruqiong Wei - [email protected]

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center #published a new brief #report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”

“In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with targeted drugs, even when used in sequence, cannot cure metastatic cancer. However, preemptive combinations of targeted drugs may, in theory, cure incurable cancer. Also, I share insights on various topics, including rapamycin, an anti-aging drug that can delay but not prevent cancer, through my personal journey.”

DOI - https://doi.org/10.18632/oncoscience.593

Corresponding author - Mikhail V. Blagosklonny - [email protected], [email protected]

Sign up for free Altmetric alerts about this article -

https://oncoscience.altmetric.com/details/email_updates?id=10.18632%2Foncoscience.593

Subscribe for free publication alerts from Oncoscience - https://www.oncoscience.us/subscribe/

Keywords - cancer, lung cancer, brain metastases, capmatinib, resistance, MET

About Oncoscience

Oncoscience is a traditional, peer-reviewed, bio-medical oncology research journal with FREE publication for authors and open-access for readers.

To learn more about Oncoscience, please visit https://www.oncoscience.us/ and connect with us:

Facebook - https://www.facebook.com/Oncoscience

X - https://twitter.com/OncoscienceJrnl

Instagram - https://www.instagram.com/oncosciencejrnl/

YouTube - https://www.youtube.com/@OncoscienceJournal

LinkedIn - https://www.linkedin.com/company/oncoscience/

Media Contact

18009220957

Lung cancer is a significant global health issue, being the second most commonly diagnosed cancer and the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) represents the majority of lung cancer cases and is often diagnosed at an advanced stage. Epidermal growth factor receptor (EGFR) mutations are more common in Asian NSCLC populations than in Western populations.

Activating EGFR mutations, such as exon 19 deletions and L858R, are predictive of response to tyrosine kinase inhibitors (TKIs) and have revolutionized the treatment landscape for patients with EGFR-mutated NSCLC. However, most clinical trials tend to lack data for the elderly population, even though a significant proportion of lung cancer patients are aged 65 years and older. This underrepresentation of elderly patients in clinical trials limits our understanding of the effectiveness and safety of EGFR-TKIs in this specific population.

In this new study, researchers Ling-Jen Hung, Ping-Chih Hsu, Cheng-Ta Yang, Chih-Hsi Scott Kuo, John Wen-Cheng Chang, Chen-Yang Huang, Ching-Fu Chang, and Chiao-En Wu from Chang Gung University and Taoyuan General Hospital conducted a multi-institute retrospective study to investigate the effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with EGFR-mutated advanced NSCLC. On January 8, 2024, their research paper was published in Aging’s Volume 16, Issue 1, entitled, “Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.”

Full blog - https://aging-us.org/2024/01/efficacy-and-safety-of-egfr-tkis-for-elderly-patients-with-nsclc/

Paper DOI - https://doi.org/10.18632/aging.205395

Corresponding author - Chiao-En Wu - [email protected]

Sign up for free Altmetric alerts about this article -

https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205395

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, elderly patients, epidermal growth factor receptor, tyrosine kinase inhibitor, non-small-cell lung cancer, real-world evidence

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Media Contact

18009220957

BUFFALO, NY- January 17, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response.”

Cancer accounts for the highest rates of morbidity and mortality worldwide. RNA binding motif protein X-linked (RBMX) is a nuclear RNA-binding protein, associated with certain types of cancer by participating in the integration of sister chromatids and a combination of ribonucleoprotein complexes. However, the specific role of RBMX in cancer immunity remains unknown.

In this new study, researchers Yilei Sheng, Kunjian Lei, Chengpeng Sun, Jia Liu, Zewei Tu, Xingen Zhu, and Kai Huang from Nanchang University, The Second Affiliated Hospital of Nanchang University, Jiangxi Key Laboratory of Neurological Tumors and Cerebrovascular Diseases, JXHC Key Laboratory of Neurological Medicine, and Yale School of Medicine present the aberrant expression levels, single-cell distributions, effective prognostic roles, immune cell infiltration associations, and immunotherapy responses of RBMX as a biomarker in various types of cancer. Moreover, they validate the aberrant expression of RBMX in clinical cancer samples.

“[...] a pan-cancer analysis is necessary for the identification of novel biological targets and biomarkers involved in carcinogenesis, cancer progression, and immunotherapy response. Such knowledge would improve the precision of cancer therapy.”

The researchers also evaluated the relationships between RBMX expression and myeloid-derived suppressor cells in clinical samples by immunofluorescent staining. Results showed that knockdown of RBMX can impair the proliferation, migration, and invasion of liver cancer cells. Finally, the team indicated that RBMX may play an immunoregulatory role in cancer progression, affecting the therapeutic effects of immune checkpoint inhibitors in patients with cancer.

“In conclusion, we performed an integrated analysis of RBMX, revealing its effective role in predicting cancer prognosis and response to immunotherapy. Abnormal expression of RBMX is associated with immune regulation, prognosis, the tumor microenvironment, immune cell infiltration, MSI, and TMB. The results of this study indicated that RBMX may play an independent role in clinical diagnosis and prediction.”

DOI - https://doi.org/10.18632/aging.205363

Corresponding authors - Zewei Tu - [email protected], Xingen Zhu - [email protected], Kai Huang - [email protected]

Sign up for free Altmetric alerts about this article -

https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205363

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, RBMX, cancer prognosis, immunotherapy response, proliferation, invasion

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Media Contact

18009220957

BUFFALO, NY- January 15, 2024 – A new #research paper was #published on the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “Effects of resveratrol on in vitro circadian clock gene expression in young and older human adipose-derived progenitor cells.”

Observational studies in preclinical models demonstrate age-related declines in circadian functions. In this new study, researchers Sophie G.C. Kapar, Maria F. Pino, Fanchao Yi, Miguel A. Gutierrez-Monreal, Karyn A. Esser, Lauren M. Sparks, and Melissa L. Erickson from AdventHealth and the University of Florida hypothesized that age would be associated with declines in function of cell-autonomous circadian clocks in human tissue.

“Accordingly, we cultured adipose progenitor cells (APCs) from previously collected white-adipose tissue biopsies from abdominal subcutaneous depots of young (Age: 23.4 ± 2.1 yrs) vs. older female participants (Age: 70.6 ± 5.9 yrs).”

Using an in vitro model, the researchers compared rhythmic gene expression profiles of core clock components, as an indicator of circadian oscillatory function. They observed consistent circadian rhythmicity of core clock components in young and older-APCs. Expression analysis showed increased levels of some components in older-APCs (CLOCK, CRY1, NR1D1) vs. young.

The team also investigated resveratrol (RSV), a well-known longevity-enhancing effector, for its effects on rhythmic clock gene expression profiles. They found that RSV resulted in gained rhythmicity of some components (CLOCK and CRY), loss of rhythmicity in others (PER2, CRY2), and altered some rhythmic parameters (NR1D1 and NR1D2), consistent in young and older-APCs. The observation of detectable circadian rhythmicity retained in vitro suggests that the oscillatory function of the cell-autonomous core clock in APCs is preserved at this stage of the aging process.

“RSV impacts core clock gene expression in APCs, implicating its potential as a therapeutic agent for longevity by targeting the core clock.”

DOI - https://doi.org/10.18632/aging.205292

Corresponding authors - Lauren M. Sparks - [email protected], and Melissa L. Erickson - [email protected]

Sign up for free Altmetric alerts about this article -

https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205292

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, circadian clock, circadian rhythm, adipose-derived progenitor cells, resveratrol

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Media Contact

18009220957

Traditional Chinese medicine has long been explored for its potential in treating various diseases, including cancer. Lithospermum erythrorhizon, or purple gromwell, is a mysterious plant native to East Asia, and its dried root is often referred to as Zicao. Acetylshikonin, a compound derived from Zicao, has shown promise in exhibiting a variety of anti-cancer properties. While the effects of acetylshikonin on lung cancer are not yet fully understood, recent research has shed light on its potential as a therapeutic agent.

In a new study, researchers Shih-Sen Lin, Tsung-Ming Chang, Augusta I-Chin Wei, Chiang-Wen Lee, Zih-Chan Lin, Yao-Chang Chiang, Miao-Ching Chi, and Ju-Fang Liu from Shin Kong Wu Ho-Su Memorial Hospital, Chang Gung Memorial Hospital, Chang Gung University of Science and Technology, Ming Chi University of Technology, Taipei Medical University, and China Medical University aimed to explore the mechanisms underlying acetylshikonin-induced cell death in non-small cell lung cancer (NSCLC). On December 19, 2023, their research paper was published in Aging’s Volume 15, Issue 24, entitled, “Acetylshikonin induces necroptosis via the RIPK1/RIPK3-dependent pathway in lung cancer.”

Full blog - https://aging-us.org/2024/01/rooted-in-chinese-medicine-zicaos-anti-cancer-effects-on-lung-cancer/

Paper DOI - https://doi.org/10.18632/aging.205316

Corresponding authors - Ju-Fang Liu - [email protected]

Sign up for free Altmetric alerts about this article -

https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205316

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, human lung cancer, acetylshikonin, ROS, necroptosis

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Media Contact

18009220957

BUFFALO, NY- January 10, 2024 – A new #editorial paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 24, entitled, “Exploring clonal hematopoiesis and its impact on aging, cancer, and patient care.”

In this new editorial, researchers Julieta Elena Rodriguez, Jean Baptiste Micol and Capucine Baldini from Gustave Roussy discuss clonal hematopoiesis. Clonal hematopoiesis (CH) is a term that refers to the presence in blood cells of hematologic malignancy-associated somatic mutations without fulfilling the diagnostic criteria of hematologic disease. Emerging evidence suggests that CH is a consequence of an expansion of cells harboring initiating driver mutations, potentially linked to the aging hematopoietic system.

While these detectable somatic mutations are rare in individuals under 40 years old, they become increasingly prevalent in the elderly population, a term called age-related clonal hematopoiesis (ARCH), reaching up to 18.4% in those aged 90 years or older. Aging itself is a significant stressor associated with CH, particularly in individuals over 70 years old. DNMT3A, TET2, and ASXL1 mutations are more common with advancing age.

“Recent evidence also indicates that CH may play a role in solid tumors, such as an increased risk of incident lung cancer [4]. While initial studies associated CH mutations with worse survival outcomes [5], newer findings suggest that solid tumor patients with CH may experience longer survival [6]. However, the underlying mechanisms behind this relationship remain to be elucidated.”

DOI - https://doi.org/10.18632/aging.205404

Corresponding author - Capucine Baldini - [email protected]

Sign up for free Altmetric alerts about this article -

https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205404

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, clonal hematopoiesis, solid tumors

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Media Contact

18009220957

BUFFALO, NY- January 9, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 24, entitled, “Systemic changes induced by autologous stem cell ovarian transplant in plasma proteome of women with impaired ovarian reserves.”

Patients with poor ovarian response (POR) and premature ovarian insufficiency (POI) are challenging to treat, with oocyte donation remaining as the only feasible option to achieve pregnancy in some cases. The Autologous stem cell ovarian transplantation (ASCOT) technique allows follicle development, enabling pregnancies and births of healthy babies in these patients. Previous research suggests that growth factors and cytokines secreted by stem cells are partially responsible for their regenerative properties. Indeed, ASCOT beneficial effects are associated with the presence of different bone marrow derived stem cell- secreted factors in plasma.

In this new study, researchers Anna Buigues, Noelia Ramírez-Martin, Jessica Martínez, Nuria Pellicer, Marcos Meseguer, Antonio Pellicer, and Sonia Herraiz from IVIRMA Global Research Alliance aimed to assess whether ASCOT induces any modifications in the plasma proteomic profile of patients with impaired ovarian reserves.

“In this study, we aimed to assess if the ASCOT technique modifies the signature of the human plasma proteome, reveal the mechanisms underlying its beneficial effects on the ovary, and identify key regulators of ovarian aging.”

Discriminant analysis highlighted clear distinctions between the plasma proteome before (PRE), during stem cell mobilization and collection (APHERESIS) and three months after ASCOT (POST) in patients with POR and POI. Both the stem cell mobilization and ASCOT technique induced statistically significant modifications in the plasma composition, reversing some age-related protein expression changes. In the POR group, functional analysis revealed an enrichment in processes related to the complement cascade, immune system, and platelet degranulation, while in the POI group, enriched processes were also associated with responses to oxygen-containing compounds and growth hormones, and blood vessel maturation.

“In conclusion, our findings highlight the potential proteins and biological processes that may promote the follicle activation and growth observed after ASCOT.”

DOI - https://doi.org/10.18632/aging.205400

Corresponding author - Sonia Herraiz - [email protected]

Sign up for free Altmetric alerts about this article -

https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205400

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, plasma proteomic profile, autologous stem cell ovarian transplantation, poor ovarian response, premature ovarian insufficiency

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Media Contact

18009220957